Daniel A Pollyea

39PUBLICATIONS
221CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapySolid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 24, 2026
A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia.

|Jul 21, 2026
The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 20, 2026
RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

|Feb 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

Michael K Jones, Jesse Sanchez, Megan Connor

|Aug 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.

Cristiana O'Brien, Nirvana Nursimulu, Anit Tyagi

Pageof 7

Frequent Collaborators

9 joint publications

Courtney D DiNardo

7 joint publications

Maria L Amaya

7 joint publications

Craig T Jordan

6 joint publications

Angelo D'Alessandro